Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma et al. · PI Clinical Trials

Primary endpoint

Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)

Population

Breast Cancer; n=991

doi:10.1056/NEJMoa1209124

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The EMILIA trial's stated primary conclusion — T-DM1 improves progression-free and overall survival vs. lapatinib+capecitabine in HER2+ advanced breast cancer. — replicates in independent cohorts.

oncology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of EMILIA are confirming the original effect size in real-world data.

oncology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, antibody-drug conjugates (T-DXd class) will have largely displaced T-DM1 as second-line HER2+ metastatic therapy.

oncology

71%

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT01958021

0.1652

· 3 claims

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

NCT01844505

0.1888

· 3 claims

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

NCT02578680

0.1971

· 3 claims

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

NCT02484547

0.1982

· 3 claims

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

NCT01035255

0.1982

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT03036488

0.1997

· 3 claims

Pembrolizumab for Early Triple-Negative Breast Cancer